by Peter Ciszewski | May 10, 2018
A review of nearly 500 cases of infants with severe congenital hyperinsulinism who underwent partial or near-total removal of their pancreas for persistent hypoglycemia at Children’s Hospital of Philadelphia (CHOP) showed that surgeons can cure virtually all...
by Peter Ciszewski | May 6, 2018
Rob Neville of Savara Pharmaceuticals provides an overview of his company’s Molgradex (for PAP and NTM lung infection) and AeroVanc (an inhaled formulation of vancomycin, for the treatment of persistent methicillin-resistant Staphylococcus aureus, or MRSA, lung...
by Peter Ciszewski | May 4, 2018
Dr. John Maraganore, CEO of Alnylam highlights the importance of diversity within his company and the biotech sector. Dr. John Maraganore has led a career pursuing therapies to address unmet medical needs. At Alnylam Pharmaceuticals, Maraganore is helping lead...
by Peter Ciszewski | May 3, 2018
Dr. Daniel Alkon of Neurotrope BioSciences discusses some of his company’s upcoming milestones, including starting a clinical trial for Fragile X. Dr. Alkon also discusses his comapy’s mechanistic approach to drup development for Bryostatin 1, which...
by Peter Ciszewski | May 2, 2018
The U.S. Food and Drug Administration (FDA) approved the combination of dabrafenib (Tafinlar) and trametinib (Mekinist) for the adjuvant treatment of patients with resected, stage III melanoma with BRAFV600 mutations. The combination is already approved for the...
